rethinkTHC Search
Menu
Study breakdown

CBD-enriched cannabis oil reduced seizures in 73% of children with drug-resistant epilepsy over at least one year

Retrospective CohortModerate evidence
The takeaway

In a retrospective study of 114 children with refractory epilepsy, 73.3% reported seizure improvement with artisanal CBD-enriched cannabis oil, and 59% of those continuing for at least one year had over 50% seizure reduction.

Parents of children with treatment-resistant epilepsy, pediatric neurologists, and researchers studying cannabinoid therapies for seizures.

59% had over 50% seizure reduction after at least one year

What the researchers found

73.3% of 114 patients reported some seizure improvement. Of 86 patients continuing treatment for at least one year, 51 (59%) showed >50% seizure reduction. Seizure etiology, type, age, and sex were not associated with response. Side effects were minor, and positive effects beyond seizure reduction were noted.

Why it matters

While RCTs have established CBD efficacy for specific epilepsy syndromes, this real-world study shows that artisanal CBD oil may help a broader range of treatment-resistant pediatric epilepsy across different etiologies.

The numbers in context

114 patients total. 84 (73.3%) reported some improvement. 86 continued for at least one year. 51 of 86 (59%) had >50% seizure reduction. Response was not predicted by etiology, seizure type, age, or sex.

How the study worked

Retrospective study of children and adolescents with refractory epilepsy from various etiologies treated with artisanal CBD-enriched cannabis oil from January 2014 to June 2019, with at least one year of follow-up.

What this study cannot tell us

Retrospective, uncontrolled design without placebo comparison. Artisanal product may vary in composition. Self/parent-reported seizure counts. Selection bias may favor patients who responded and continued treatment.

How to read the evidence

Moderate: reasonable sample size with long-term follow-up, but retrospective, uncontrolled, and using artisanal product.

When this study was published

Published in 2022.

The bigger picture

The finding that response was not predicted by seizure etiology or type suggests CBD-enriched oil may have broad applicability in drug-resistant pediatric epilepsy, not just the specific syndromes studied in clinical trials.

Questions still open

  • Would these results hold up in a controlled trial? What is the optimal CBD:THC ratio for seizure control? Why does seizure etiology not predict response? How long do benefits persist beyond one year?

Common questions

What type of CBD product was used?
Artisanal (non-pharmaceutical) CBD-enriched cannabis oil, which may differ from pharmaceutical-grade CBD products like Epidiolex in composition and standardization.
Did all types of epilepsy respond equally?
The study found no significant difference in response based on seizure etiology, seizure type, patient age, or sex, suggesting broad applicability.
Were there significant side effects?
Side effects were described as minor, and positive effects beyond seizure reduction were noted, though specific adverse events were not detailed.

Read the original research

The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy.

Pediatric neurology, 136, 15-19

Citation

Tzadok, Michal; Hamed, Nasrin; Heimer, Gali; Zohar-Dayan, Efrat; Rabinowicz, Shira; Ben Zeev, Bruria. (2022). The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy.. Pediatric neurology, 136, 15-19. https://doi.org/10.1016/j.pediatrneurol.2022.06.016

Explore the wider topic